Top Biotech Insider Quietly Makes a Bold Move That Could Signal What’s Coming Next

New insider activity at Tempest Therapeutics ( (TPST) ) has taken place on March 25, 2026.Claim 30% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Tempest Therapeutics has drawn insider confidence as CEO & President Angel Matthew purchased 231,482 shares of the company’s stock in a recent transaction, representing a total investment of $500,001. Recent Updates on TPST stock Tempest Therapeutics’ shares have reacted to news of a small but structured private placement that modestly boosts liquidity while attempting to limit near‑term dilution via warrant-based financing and a brief post‑registration lock‑up on new equity. Analysts kept a neutral stance, citing ongoing losses, cash burn, weak technicals, and valuation constraints despite encouraging TPST‑2003 CAR‑T data that show high response rates in multiple myeloma and a new CDMO partnership that supports further development. Spark’s Take on TPST Stock According to Spark, TipRanks’ AI Analyst, TPST is a Neutral. The score is primarily held down by weak financial performance (no revenue, ongoing losses, and significant cash burn with a shrinking equity cushion). Technicals remain soft with price below key longer-term averages and negative MACD. Corporate events are mixed (Nasdaq compliance risk vs. governance approvals), and valuation metrics offer limited support due to negative earnings and no dividend. To see Spark’s full report on TPST stock, click here. More about Tempest Therapeutics YTD Price Performance: -39.02% Average Trading Volume: 110,020 Technical Sentiment Signal: Sell Current Market Cap: $24.81M